H. Grossman

发表

Cell-specific ribosomal DNA spacer variability in human urothelial carcinoma cultures.

G. Wilson, M. Dasouki, H. Grossman, 1987, The Journal of urology.

Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design

C. Dinney, A. Kamat, V. Narayan, 2021, The Journal of urology.

Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography.

R. Wahl, D. Kuhl, J. Harney, 1991, The Journal of urology.

Decreased connexin expression and intercellular communication in human bladder cancer cells.

S. W. Lee, I. Lee, H. Grossman, 1994, Cancer research.

Blood group antigens and integrins as biomarkers in head and neck cancer: Is aberrant tyrosine phosphorylation the cause of altered α6β4 integrin expression?

C. Van Waes, T. Carey, G. Wolf, 1993 .

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.

C. Dinney, L. Pagliaro, J. Slaton, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N-(4-hydroxyphenyl)retinamide (4-HPR) modulates GADD45 expression in radiosensitive bladder cancer cell lines.

Li-E. Wang, Q. Wei, C. Zou, 2002, Cancer letters.

Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA

J. Witjes, B. Bochner, N. Smith, 2014, Nature Reviews Urology.

Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection.

C. Dinney, John W. Davis, M. Munsell, 2011, The Journal of urology.

Pathologic evaluation of radical cystectomy specimens

E. Crawford, H. Herr, H. Grossman, 2004, Cancer.

WHAT IS THE BIOLOGY OF INVASION AND METASTASIS IN BLADDER CANCER?

Philip Smith, M. Tachibana, T. Kakizoe, 1995, International journal of urology : official journal of the Japanese Urological Association.

Clinical outcomes of cT1 micropapillary bladder cancer.

B. Czerniak, S. Parikh, C. Dinney, 2015, The Journal of urology.

Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.

R. Millikan, S. Groshen, B. Czerniak, 2014, The Journal of urology.

Use of Fluorescence in situ Hybridization to Predict Patient Response to BCG Therapy for Bladder Cancer: Results of a Prospective Trial

C. Dinney, A. Kamat, R. Katz, 2012 .

Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study.

J. Paradelo, E. Crawford, B. Blumenstein, 1997, The Journal of urology.

Alterations in antigen expression in superficial bladder cancer

T. Carey, H. Grossman, M. Liebert, 1992, Journal of cellular biochemistry. Supplement.

Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males

W. Sakr, L. Wideroff, T. Carey, 1996, The Prostate.

The uptake and efflux of doxorubicin by a sensitive human bladder cancer cell line and its doxorubicin-resistant subline.

J. Wagner, G. Wedemeyer, H. Grossman, 1991, Selective cancer therapeutics.

Evaluation of multiple drug resistance in human bladder cancer cell lines.

J. Chang, N. Shinohara, G. Wedemeyer, 1993, The Journal of urology.

OUTCOME OF BLADDER CANCER PATIENTS WITH pN+ DISEASE AFTER PREOPERATIVE CHEMOTHERAPY AND RADICAL CYSTECTOMY

M. Munsell, A. Kamat, W. Kassouf, 2009 .

Comparing the effect of ATRA, 4-HPR, and CD437 in bladder cancer cells.

C. Zou, Xinru Wang, Jianwei Zhou, 2006, Frontiers in bioscience : a journal and virtual library.

p53 and RB expression predict progression in T1 bladder cancer.

C. Dinney, W. F. Benedict, J. Palmer, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma

R. Millikan, V. Margulis, C. Wood, 2010, Cancer.

Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center.

R. Millikan, C. Dinney, S. Matin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy for bladder cancer

H. Grossman, C. Dinney, P. Black, 2006, World Journal of Urology.

Surgical factors influence bladder cancer outcomes: a cooperative group report.

H. Grossman, R. deVere White, E. Crawford, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy.

C. Dinney, M. Munsell, A. Kamat, 2006, The Journal of urology.

Management of urethral recurrence after orthotopic urinary diversion

C. Dinney, M. Munsell, A. Kamat, 2009, BJU international.

The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma.

R. Millikan, C. Dinney, A. Kamat, 2006, The Journal of urology.

The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer.

S. Parikh, C. Dinney, S. Matin, 2012, Urologic oncology.

Identification by monoclonal antibodies of an antigen shed by human bladder cancer cells.

G. Wedemeyer, A. Flint, H. Grossman, 1989, Cancer research.

The Monoclonal Antibody BQ16 Identifies the α6β4 Integrin on Bladder Cancer

C. Waes, T. Carey, G. Wedemeyer, 1993 .

The monoclonal antibody BQ16 identifies the alpha 6 beta 4 integrin on bladder cancer.

C. Van Waes, T. Carey, G. Wedemeyer, 1993, Hybridoma.

Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells

M. Welsh, E. Prochownik, J. Harney, 1991, Molecular and cellular biology.

Serum sialic acid is a biologic marker for malignant disease

H. Grossman, U. Khanderia, J. Keller, 1983, Journal of surgical oncology.

Repeated I ntravesical I nstillations o f a n A denoviral V ector i n Patients W ith L ocally A dvanced B ladder C ancer: A P hase I Study o f p53 Gene T herapy

C. Dinney, L. Pagliaro, J. Slaton, 2003 .

Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?

C. Wood, C. Dinney, S. Matin, 2006, BJU international.

P-glycoprotein expression in bladder cancer.

N. Shinohara, A. Flint, H. Grossman, 1994, The Journal of urology.

All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors

C. Dinney, Charles C. Guo, A. Kamat, 2022, The Journal of urology.

Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.

J. Crowley, M. Leblanc, I. Thompson, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Loss of co-localization of alpha 6 beta 4 integrin and collagen VII in bladder cancer.

T. Carey, G. Wedemeyer, H. Grossman, 1994, The American journal of pathology.

Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology

E. Messing, I. Thompson, C. Tangen, 2011 .

Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.

C. Dinney, A. Kamat, D. Urbauer, 2016, European urology.

Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial.

Xifeng Wu, C. Dinney, A. Kamat, 2012, The Journal of urology.

Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery

H. Grossman, M. Tanaka, M. Liebert, 2001, Gene Therapy.

Blood group antigens and integrins as biomarkers in head and neck cancer: is aberrant tyrosine phosphorylation the cause of altered alpha 6 beta 4 integrin expression?

C. Van Waes, T. Carey, G. Wolf, 1993, Journal of cellular biochemistry. Supplement.

Evaluation of N‐acetylneuraminic acid, carcinoembryonic antigen, and alpha‐fetoprotein as markers for advanced carcinoma

H. Grossman, Ujjaini Khanderia, 1988, Journal of surgical oncology.

Urothelial differentiation and bladder cancer.

H. Grossman, C. Wood, H. Grossman, 1999, Advances in experimental medicine and biology.

MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells

Michael A Davies, Motoyoshi Tanaka, P. Steck, 2000, Oncogene.

Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.

J. Gu, Xifeng Wu, C. Dinney, 2010, Carcinogenesis.

Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer.

P. Thall, R. Millikan, C. Dinney, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder

B. Czerniak, C. Dinney, M. Munsell, 2007, Cancer.

Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease.

C. Dinney, A. Kamat, Roger Li, 2019, European urology.

The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non‐muscle‐invasive bladder cancer treated with bacillus Calmette–Guérin

C. Dinney, Jianjun Gao, Yu Shen, 2020, BJU International.

Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer

Jian Gu, Yuanqing Ye, Xifeng Wu, 2008, Cancer.

Time interval from transurethral resection of bladder tumour to bacille Calmette–Guérin induction does not impact therapeutic response

C. Dinney, A. Kamat, Roger Li, 2021, BJU international.

Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center.

R. Millikan, C. Dinney, S. Matin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

H. Grossman, G. Sonpavde, V. Speights, 2009, Cancer.

Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation

D. Kuban, H. Grossman, T. McDonnell, 2004, Cancer Gene Therapy.

Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC.

C. Dinney, M. Munsell, P. Spiess, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1240: Prospective Evidence Supporting the Utility of Neooadjuvant Chemotherapy in Small Cell Urothelial Cancer: Preliminary Results from A Phase II Clinical Trial at the M.D. Anderson Cancer Center

R. Millikan, C. Dinney, A. Kamat, 2006 .

Tumorigenesis and Neoplastic Progression Loss of 15-Hydroxyprostaglandin Dehydrogenase Expression Contributes to Bladder Cancer Progression

C. Wood, H. Kintner, J. Gee, 2010 .

Micropapillary bladder cancer

P. Tamboli, C. Dinney, A. Kamat, 2007, Cancer.

The role of radical cystectomy in patients with clinical T4b bladder cancer.

C. Dinney, M. Munsell, A. Kamat, 2011, Urologic oncology.

Bladder cancer risk as modified by family history and smoking

M. Spitz, Xifeng Wu, C. Dinney, 2006, Cancer.

Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?

K. Do, B. Czerniak, C. Dinney, 2006, Urology.

Correlation between annual volume of cystectomy, professional staffing, and outcomes

C. Dinney, L. Elting, B. Bekele, 2005, Cancer.

P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors.

C. Dinney, M. Munsell, P. Spiess, 2007, European urology.

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer – A New Analysis

J. Witjes, Michael Cookson, A. Kamat, 2016, Bladder cancer.

Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer

B. Czerniak, S. Parikh, C. Dinney, 2017, BJU international.

Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710)

E. Messing, I. Thompson, C. Tangen, 2010, BJU international.

18F‐2‐deoxy‐2‐fluoro‐D‐glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron‐emission tomography

R. Wahl, G. Hutchins, D. Buchsbaum, 1991, Cancer.

High‐Frequency Endoluminal Ultrasonography as an Aid to the Staging of Upper Tract Urothelial Carcinoma

S. Matin, A. Kamat, H. Grossman, 2010, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy

C. Dinney, M. Munsell, A. Kamat, 2012, BJU international.

Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy.

C. Dinney, S. Matin, A. Kamat, 2011, Urology.

Laparoscopy and Robotics Perioperative Outcomes of Laparoscopic Radical Nephroureterectomy and Regional Lymphadenectomy in Patients With Upper Urinary Tract Urothelial Carcinoma After Neoadjuvant Chemotherapy

C. Dinney, S. Matin, A. Kamat, 2011 .

Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes.

C. Dinney, S. Matin, A. Kamat, 2013, International braz j urol : official journal of the Brazilian Society of Urology.

Seminar article Neoadjuvant chemotherapy for bladder cancer

R. Millikan, A. Siefker-Radtke, H. Grossman, 2003 .

Risk group stratification in patients with micropapillary bladder cancer treated with radical cystectomy and/or neoadjuvant chemotherapy.

B. Czerniak, S. Parikh, C. Dinney, 2015 .

E‐cadherin promoter polymorphism (C‐160A) and risk of recurrence in patients with superficial bladder cancer

M. Spitz, Y. Zhu, M. Jhamb, 2006, Clinical genetics.

Association of Polymorphisms in Oxidative Stress Genes with Clinical Outcomes for Bladder Cancer Treated with Bacillus Calmette-Guérin

Xifeng Wu, C. Dinney, D. Chang, 2012, PloS one.

EFFECT OF RETINOIC ACID AND INTERFERON α-2a ON TRANSITIONAL CELL CARCINOMA OF BLADDER

R. Lotan, S. Ramakumar, C. Zou, 2005 .

Anterior fascial fixation does not reduce the parastomal hernia rate after radical cystectomy and ileal conduit.

A. Kamat, Wei Wei, Jun Liu, 2014, Urology.

463: Management of Primary Carcinomas of the Male Urethra

C. Dinney, P. Spiess, A. Kamat, 2006 .

Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.

Wassim Kassouf, C. Dinney, M. Munsell, 2006, The Journal of urology.

Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.

C. Dinney, A. Kamat, J. Shah, 2016, European urology.

Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity

C. Dinney, M. Munsell, A. Kamat, 2010, BJU international.

A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer

R. Millikan, C. Dinney, Yu Shen, 2013, Cancer.

Review of the M.D. Anderson experience in the treatment of bladder sarcoma.

B. Czerniak, C. Dinney, P. Spiess, 2007, Urologic oncology.

Clinical significance of ureteric ‘skip lesions’ at the time of radical cystectomy: the M.D. Anderson experience and literature review

C. Wood, C. Dinney, A. Kamat, 2014, BJU international.

Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy.

C. Dinney, A. Kamat, J. Shah, 2014, Urology.

Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction.

C. Dinney, P. Spiess, A. Kamat, 2008, The Journal of urology.

A phase II trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine (IAG), followed by cisplatin, gemcitabine and ifosfamide (CGI) in locally advanced urothelial cancer (UC): Final results from the M.D. Anderson Cancer Center

R. Millikan, C. Dinney, Yu Shen, 2008 .

915: The Case for Early Cystectomy in Non-Muscleinvasive Micropapillary Transitional Cell Carcinoma of the Bladder

R. Millikan, C. Dinney, A. Kamat, 2005 .

Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era

C. Dinney, M. Munsell, A. Kamat, 2006, Cancer.

Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria.

C. Dinney, S. Matin, K. Kennedy, 2010, The Journal of urology.

Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes.

C. Dinney, A. Kamat, Roger Li, 2021, European urology oncology.

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.

C. Dinney, A. Kamat, Roger Li, 2019, European urology oncology.

Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the University of Texas M. D. Anderson Cancer Center.

R. Millikan, C. Dinney, S. Matin, 2012 .

Stimulated urothelial cells produce cytokines and express an activated cell surface antigenic phenotype.

L. Abruzzo, S. Kunkel, G. Wedemeyer, 1991, Seminars in urology.

Evidence for urothelial cell activation in interstitial cystitis.

G. Wedemeyer, G. Faerber, A. Flint, 1993, The Journal of urology.

G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.

R. Hurst, G. Hemstreet, B. Bane, 1998, Journal of cellular biochemistry. Supplement.

Organ preservation for muscle-invasive bladder cancer by transurethral resection.

Xifeng Wu, C. Dinney, C. Pettaway, 2007, Urology.

1521: Variant Histology in Bladder Cancer - Experience in 1246 Patients Undergoing Cystectomy

R. Millikan, C. Dinney, M. Munsell, 2007 .

The expression of epidermal growth factor receptor on human bladder cancer: potential use in radioimmunoscintigraphy.

J. Harney, Z. Steplewski, G. Wedemeyer, 1991, The Journal of urology.

G‐actin as a risk factor and modulatable endpoint for cancer chemoprevention trials

R. Hurst, G. Hemstreet, B. Bane, 1996 .

Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: Final results

R. Millikan, C. Dinney, Yu Shen, 2013 .

Expression of the VLA beta 1 integrin family in bladder cancer.

G. Wedemeyer, H. Grossman, M. Liebert, 1994, The American journal of pathology.

Outcome analysis of 42 cases of renal angiomyolipoma.

H. Grossman, M. Kennelly, K. Cho, 1994, The Journal of urology.

Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer

L. Kiemeney, U. Thorsteinsdóttir, K. Stefánsson, 2009, Nature Genetics.

Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

D. Lamm, H. Grossman, J. Efstathiou, 2015, Nature Reviews Urology.

Projecting individualized probabilities of developing bladder cancer in white individuals.

M. Spitz, J. Gu, Xifeng Wu, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Urinary tract diseases and bladder cancer risk: a case–control study

Jie Lin, Xifeng Wu, Xifeng Wu, 2007, Cancer Causes & Control.

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

D. Lamm, H. Grossman, J. Montie, 2000, The Journal of urology.

Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies.

R. Wahl, H. Grossman, J. Harney, 1991, The Journal of urology.

Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.

H. Grossman, J. Witjes, Yu Shen, 2010, The Journal of urology.

The relationship of local control to distant metastasis in muscle invasive bladder cancer.

H. Grossman, C. Dinney, A. Pollack, 1995, The Journal of urology.

Focus on bladder cancer.

R. Millikan, A. Sabichi, Xifeng Wu, 2004, Cancer cell.

Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center.

R. Millikan, H. Grossman, C. Dinney, 2013, European urology.

Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy.

H. Grossman, C. Dinney, S. Matin, 2007, Urology.

MP60-12 MULTI-INSTITUTIONAL QUALITY CARE INITIATIVE TO IMPROVE THE CARE OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER

P. Black, M. Gleave, A. Kibel, 2014 .

Malignant mesothelioma of the tunica vaginalis.

H. Grossman, B. Czerniak, P. Spiess, 2005, Urology.

Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression.

A. Sabichi, H. Grossman, W. Benedict, 2006, The Journal of urology.

Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder.

H. Grossman, C. Dinney, R. Veltri, 1998, The Journal of urology.

Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

C. Dinney, W. Benedict, B. Hutchins, 2013, The Journal of urology.

Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Interferon-Induced Apoptosis in Human Bladder Cancer Cells

R. Millikan, H. Grossman, C. Dinney, 2004, Cancer Research.

Upper urinary tract tumors with nontransitional histology: a single-center experience.

H. Grossman, P. Tamboli, C. Dinney, 2006, Urology.

Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer.

P. Scardino, D. Lamm, H. Grossman, 1990, The Journal of urology.

Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center.

R. Millikan, C. Dinney, Yu Shen, 2013, European urology.

Management of urethral recurrence after orthotopic urinary diversion

C. Dinney, M. Munsell, A. Kamat, 2009, BJU international.

Malignant melanoma of the penis and male urethra.

A. Diokno, P. Sogani, H. Grossman, 1984, The Journal of urology.

Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria.

C. Dinney, S. Matin, K. Kennedy, 2010, The Journal of urology.